All patients
Age < 65y (younger) Age > 65y Asian type cancer location (gastric) cancer location (gastro-esophageal) cancer type (metastatic) ECOG 0 ECOG 1 Gender, female Gender, male previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced mGC or mGEJC, pembrolizumab based treatment vs. non platinum-based chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.79; 1.12]
KEYNOTE-061 (PDL1 CPS>1), 2018 0.82 [0.66; 1.02]
0.89 [0.78 ; 1.02 ] KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018 2 0% 987 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-061 (all population), 2018 1.49 [1.25; 1.77]
KEYNOTE-061 (PDL1 CPS>1), 2018 1.27 [1.03; 1.57]
1.39 [1.19 ; 1.62 ] KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018 2 24% 987 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-061 (all population), 2018 0.88 [0.53; 1.45]
KEYNOTE-061 (PDL1 CPS>1), 2018 1.20 [0.68; 2.09]
1.01 [0.69 ; 1.46 ] KEYNOTE-061 (all population), 2018, KEYNOTE-061 (PDL1 CPS>1), 2018 2 0% 987 moderate not evaluable TRAE (any grade)detailed results KEYNOTE-061 (all population), 2018 0.21 [0.14; 0.31]
0.21 [0.14 ; 0.31 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.31 [0.21; 0.47]
0.31 [0.21 ; 0.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-061 (all population), 2018 2.84 [0.29; 27.42]
2.84 [0.29 ; 27.42 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-061 (all population), 2018 0.55 [0.24; 1.28]
0.55 [0.24 ; 1.28 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
0.16 [0.01 ; 3.11 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.54 [0.21; 1.38]
0.54 [0.21 ; 1.38 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.16 [0.01; 3.11]
0.16 [0.01 ; 3.11 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.06; 15.08]
0.94 [0.06 ; 15.08 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.49 [0.19; 1.26]
0.49 [0.19 ; 1.26 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 7.60 [0.40; 144.43]
7.60 [0.40 ; 144.43 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.94 [0.02; 47.47]
0.94 [0.02 ; 47.47 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.47 [0.02 ; 14.02 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.04; 5.19]
0.47 [0.04 ; 5.19 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.02 [0.00; 0.25]
0.02 [0.00 ; 0.25 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.47 [0.02; 14.02]
0.47 [0.02 ; 14.02 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 0.08 [0.00; 1.38]
0.08 [0.00 ; 1.38 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 3.77 [0.17; 84.06]
3.77 [0.17 ; 84.06 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-061 (all population), 2018 1.88 [0.06; 56.28]
1.88 [0.06 ; 56.28 ] KEYNOTE-061 (all population), 2018 1 0% 570 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 21:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 273,122,271,262,260,219,184,272,123,187,185,186,304
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561